drugset / Trial / NCT03603964

Guadecitabine Extension Study

NCT03603964

Phase 2 Terminated 35 enrolled Astex Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study \[including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)\].

Timeline

Start
2018-07-18
Primary completion
2021-10-04
Completion
2021-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Guadecitabine Oligonucleotide (other) Subcutaneous